EPO and colonic neoplasm: Similar results were obtained in previous studies, in which we observed that the combined use of Epo and cytotoxic agents such as 5-fluorouacil and active metabolite of irinotecan (SN-38) enhanced the antitumor effect on DLD-1 human colon cancer cells [20].